首页>
外国专利>
USE OF PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS FOR TREATING CONTRAST -INDUSED NEPHROPATHY
USE OF PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS FOR TREATING CONTRAST -INDUSED NEPHROPATHY
展开▼
机译:垂体腺苷酸环化酶激活多肽(PACAP)和PACAP类似物治疗对比剂诱发的肾病
展开▼
页面导航
摘要
著录项
相似文献
摘要
Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/ therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media. Also featured is an in vivo mouse model for testing the efficacy of cytoprotective agents against contrast-induced nephropathy.
展开▼